Skip to content

Construction of siRNA loaded nano MgO/PLLA targeted drug delivery system and its application in preventing and treating oral leukoplakia malignancy

Construction of siRNA loaded nano MgO/PLLA targeted drug delivery system and its application in preventing and treating oral leukoplakia malignancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116245
Enrollment
Unknown
Registered
2026-01-07
Start date
2026-01-31
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral leukoplakia

Interventions

Oral leukoplakia group:None
Healthy control group:None

Sponsors

Stomatological Hospital of Shanxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The patient who visited the Stomatological Hospital of Shanxi Medical University from January 2026 to December 2029 had OLK clinical diagnosis that met the WHO diagnostic criteria; 2. The age range is between 18-70 years old; 3. Individuals without a history of systemic diseases or other immune related illnesses; 4. The lesion site is the oral mucosa. B exclusion criteria; 1. From January 2026 to December 2029, the patients were treated in the Department of oral and maxillofacial surgery, Stomatological Hospital of Shanxi Medical University for tooth extraction and gingival repair; 2. The age range is 18-70 years old; 3.No history of systemic diseases or other immune diseases; 4. There was no history of olk and other oral mucosal diseases;

Exclusion criteria

Exclusion criteria: 1. Those who have used hormones and immune drugs within the past 3 months; 2. Patients with other mucosal diseases or malignant tumors in the oral cavity, and those with acute inflammation in the oral cavity, such as wisdom tooth periodontitis and gingival abscess; 3. Suffering from severe systemic diseases, having undergone bone marrow transplantation, hepatitis C virus infection, chronic lupus erythematosus, and Sjogren's syndrome. Exclusion criteria: 1. those who used hormones and immune agents within 3 months; 2. Patients with other mucosal diseases or malignant tumors in the mouth, acute inflammation in the mouth, such as pericoronitis of wisdom teeth and gingival abscess; 3. Patients with severe systemic diseases, previous bone marrow transplantation, hepatitis C virus infection, chronic lupus erythematosus and Sjogren's syndrome

Design outcomes

Primary

MeasureTime frame
Expression level of FAP;

Countries

China

Contacts

Public ContactRan Li

Stomatological Hospital of Shanxi Medical University

lraner@163.com+86 351 4690868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026